DOW JONES22,327.48+690.70 3.19%
S&P 5002,626.65+85.18 3.35%
NASDAQ7,774.15+271.77 3.62%

HC Wainwright & Co. Maintains Buy on Galectin Therapeutics, Lowers Price Target to $9

HC Wainwright & Co. analyst Ed Arce maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and lowers the price target from $11 to $9.

Benzinga · 03/17/2020 11:34

HC Wainwright & Co. analyst Ed Arce maintains Galectin Therapeutics (NASDAQ:GALT) with a Buy and lowers the price target from $11 to $9.